Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2025-03-18 Sale |
2025-03-20 4:33 pm |
CytomX Therapeutics Inc. | CTMX | Ogden Christopher Chief Financial Officer |
8,551 | $0.599 | $5,122 | 201,026 (Direct) |
View |
| 2024-08-20 Sale |
2024-08-22 5:59 pm |
CytomX Therapeutics Inc. | CTMX | Ogden Christopher Chief Financial Officer |
1,984 | $1.2291 | $2,439 | 108,077 (Direct) |
View |
| 2024-03-19 Sale |
2024-03-21 4:38 pm |
CytomX Therapeutics Inc. | CTMX | Ogden Christopher SVP, Finance and Accounting |
2,971 | $2.0855 | $6,196 | 85,686 (Direct) |
View |
| 2023-12-20 Sale |
2023-12-22 4:10 pm |
CytomX Therapeutics Inc. | CTMX | Ogden Christopher SVP, Finance and Accounting |
1,990 | $1.3806 | $2,747 | 48,657 (Direct) |
View |
| 2023-03-16 Sale |
2023-03-20 6:43 pm |
CytomX Therapeutics Inc. | CTMX | Ogden Christopher SVP, Finance and Accounting |
516 | $1.9793 | $1,021 | 37,772 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-02-04 Option Award |
2025-02-06 5:55 pm |
N/A 2035-02-03 |
CytomX Therapeutics Inc. | CTMX | Ogden Christopher Chief Financial Officer |
441,500 | $0 | 549,577 (Direct) |
View |
| 2024-08-20 Exercise |
2024-08-22 5:59 pm |
N/A N/A |
CytomX Therapeutics Inc. | CTMX | Ogden Christopher Chief Financial Officer |
6,875 | $0 | 108,077 (Direct) |
View |
| 2024-06-12 Option Award |
2024-06-14 4:24 pm |
N/A 2034-06-11 |
CytomX Therapeutics Inc. | CTMX | Ogden Christopher Chief Financial Officer |
92,500 | $0 | 178,186 (Direct) |
View |
| 2024-01-18 Option Award |
2024-01-19 8:41 pm |
N/A 2034-01-17 |
CytomX Therapeutics Inc. | CTMX | Ogden Christopher SVP, Finance and Accounting |
269,000 | $0 | 317,657 (Direct) |
View |
| 2023-12-17 Exercise |
2023-12-19 7:58 pm |
N/A N/A |
CytomX Therapeutics Inc. | CTMX | Ogden Christopher SVP, Finance and Accounting |
6,875 | $0 | 57,522 (Direct) |
View |
| 2023-02-02 Option Award |
2023-02-06 4:47 pm |
N/A 2033-02-01 |
CytomX Therapeutics Inc. | CTMX | Ogden Christopher SVP, Finance and Accounting |
175,000 | $0 | 188,288 (Direct) |
View |
| 2022-08-10 Option Award |
2022-08-12 4:59 pm |
N/A 2032-08-09 |
CytomX Therapeutics Inc. | CTMX | Ogden Christopher SVP, Finance and Accounting |
96,250 | $0 | 96,250 (Direct) |
View |
Ownership |
2022-03-09 6:06 pm |
N/A N/A |
CytomX Therapeutics Inc. | CTMX | Ogden Christopher See Remarks |
0 | $0 | 89,863 (Direct) |
View |